Bridge Bio Eidosibute ( AG10) in phase III for ATTRcm is a new opction for ouers Amilos whith transtirretin. #Acoramidis #ATTRCM #PhaseIII #SOMOSAMILO www.amilo.es
Our transthyretin amyloidosis (ATTR) team is heading to ESC Heart Failure hosted by European Society of Cardiology! This year, we will be sharing updates from our ATTRibute-CM Phase 3 trial in one oral presentation and three moderated poster presentations. We will also be supporting a Satellite Symposium with leading physicians in the cardiology space. Check out our website to learn about our latest news: bridgebio.com/what-is-attr